#USA #Irvine #CAR-T therapy #PeproMene Bio #PMB-CT01

PeproMene Bio's Breakthrough in CAR-T Therapy at EHA 2026

PeproMene Bio, Inc. recently made headlines by announcing its upcoming oral presentation at the 2026 Annual Congress of the European Hematology Association (EHA), showcasing groundbreaking findings from its clinical trial of PMB-CT01, a novel CAR-T therapy targeting the B-cell activation factor receptor (BAFF-R). This data represents a significant advancement in the treatment landscape for patients with relapsed or refractory B-cell lymphomas, especially those who have previously failed CD19-directed therapies.

Promising Results from Clinical Trial

During the ongoing Phase 1 study, PeproMene Bio assessed the safety and efficacy of PMB-CT01 in patients suffering from non-Hodgkin's lymphoma (NHL) that is both recurrent and refractory. The results from the dose escalation portion of the trial involved nine patients, unveiling a promising safety profile with no dose-limiting toxicities recorded. Notably, there were also no instances of cytokine release syndrome (CRS) exceeding grade 1, nor any grade 1 or higher immune effector cell-associated neurotoxicity syndrome (ICANS).

The findings indicated that 78% of the patients (seven out of nine) achieved a complete response (CR), showcasing the efficacy of PMB-CT01 in a patient population where therapeutic options are critically limited. At the latest data cut-off, no relapses had occurred, with all initial responses still ongoing, including the longest response period that exceeded three years. Impressively, those who responded to the treatment also tested negative for minimal residual disease (MRD), suggesting deep remission without detectable cancer cells remaining in their systems.

Expanding Patient Cohorts

Encouraged by these results, the trial is now in an active recruitment phase for additional patient cohorts, specifically targeting mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma. A highlight among these expansions includes the treatment of a transformed follicular lymphoma (tFL) patient who had experienced progression following CD19 CAR-T therapy; this patient achieved a complete response during their first disease assessment. tFL is known for its aggressive nature and traditionally limited therapeutic avenues.

Clinical Implications of the Findings

Dr. Larry W. Kwak, M.D., Ph.D., the scientific founder of PeproMene Bio, articulated the paramount need for innovative treatment options in these patients. He emphasized, “When cancer progresses after CD19 CAR-T therapy, patients face a significant unmet medical need, as remaining treatment options are markedly constrained. These durable complete responses lend clinical validation to BAFF-R as a promising new target, while the favorable safety profile observed thus far may support future applications in outpatient community oncology settings and further explorations in refractory autoimmune diseases.”

Presentation Details

The significant presentation will cover topics such as:

• - Title of Presentation: Durable responses and favorable safety of BAFF-R CAR T-cells (PMB-CT01) in patients with relapsed/refractory B-cell lymphomas after prior CD19-directed therapy failure or CD19-negative disease.
• - Abstract code: EHA-1611 S287
• - Date/Time: June 14, 11:00 AM - 12:15 PM CEST
• - Presenter: Dr. Larry W. Kwak, M.D., Ph.D.

About PMB-CT01

PMB-CT01 stands out as the first autologous CAR-T therapy targeting BAFF-R and is currently being evaluated for both recurrent/refractory B-NHL and B-ALL in ongoing Phase 1 trials. The targeting of BAFF-R is particularly strategic since it is predominantly expressed on B-cells, playing a vital role in their survival while minimizing the risk of antigen escape.

About PeproMene Bio

Located in Irvine, California, PeproMene Bio, Inc. is a clinical-stage biotechnology company committed to developing innovative therapies for cancer and immune-related conditions. For further inquiries, reach out to Dr. Hazel Cheng, the Chief Operating Officer at PeproMene Bio, Inc., at email protected] or visit their website at [pepromenebio.com.

This announcement about PeproMene Bio’s developments signifies a potential leap forward in transforming treatment paradigms while addressing a critical need for patients battling resistant forms of lymphoma.